You are here

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must consent in writing to participate in the study.

- Patients must be willing to comply with study visit schedule and study requirements,
including, for women of child-bearing potential or male patients with female partners
of child-bearing potential, the use of 2 forms of birth control, one of which is a
barrier method.

- Patients must have participated in the A4091026 study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Withdrawn from the A4091026 study for an adverse event or serious adverse event.

- Pregnant women, lactating mothers, women suspected of being pregnant, and women who
wish to be pregnant during the course of clinical study.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the patient
inappropriate for entry into this study.

NCT00960804
Pfizer
Terminated
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
Official Title  ICMJE A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip
Brief SummaryTanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
Detailed DescriptionThis study was terminated on 11 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis
Intervention  ICMJE
  • Biological: Tanezumab
    IV, 5 mg dose, q 8 weeks, for up to 80 weeks
  • Biological: Tanezumab
    IV, 10 mg dose, q 8 weeks, for up to 80 weeks
  • Other: Placebo
    IV, q 8 weeks, for up to 80 weeks
Study Arms  ICMJE
  • Experimental: Tanezumab 5 mg
    Intervention: Biological: Tanezumab
  • Experimental: Tanezumab 10 mg
    Intervention: Biological: Tanezumab
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 16, 2010)
21
Original Estimated Enrollment  ICMJE
 (submitted: August 17, 2009)
220
Actual Study Completion Date  ICMJE November 2010
Actual Primary Completion DateNovember 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must consent in writing to participate in the study.
  • Patients must be willing to comply with study visit schedule and study requirements, including, for women of child-bearing potential or male patients with female partners of child-bearing potential, the use of 2 forms of birth control, one of which is a barrier method.
  • Patients must have participated in the A4091026 study.

Exclusion Criteria:

  • Withdrawn from the A4091026 study for an adverse event or serious adverse event.
  • Pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to be pregnant during the course of clinical study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location CountriesCanada,   United States
 
Administrative Information
NCT Number  ICMJE NCT00960804
Other Study ID Numbers  ICMJE A4091040
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now